Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018, 61: 2118-2125. PMID: 30132031, DOI: 10.1007/s00125-018-4663-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsWeight LossConceptsSGLT2 inhibitorsSodium-glucose cotransporter 2 inhibitorsPostprandial blood glucose levelsEuglycaemic diabetic ketoacidosisGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetic kidney diseaseGenitourinary tract infectionsLower extremity amputationHigh-risk individualsBlood glucose levelsPlasma glucose concentrationCardiovascular outcomesDiabetic ketoacidosisUrinary frequencyTract infectionsOptimal prescribingNew drug categoryKidney diseaseGlucose reabsorptionGlucose levelsHigh riskDrug categoriesBody weightBone fracturesDiabetes medications and cardiovascular disease
Lupsa BC, Inzucchi SE. Diabetes medications and cardiovascular disease. Current Opinion In Endocrinology Diabetes And Obesity 2018, 25: 87-93. PMID: 29369916, DOI: 10.1097/med.0000000000000400.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesHumansHyperglycemiaHypoglycemic AgentsMetforminRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsConceptsCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitus patientsPeptide-1 receptor agonistsGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetes mellitus patientsType 2 diabetesCause of mortalityCardiovascular complicationsCardiovascular outcomesDiabetes medicationsMicrovascular complicationsCardiovascular effectsMellitus patientsReceptor agonistDrug categoriesIntensive controlDiseaseComplicationsMedicationsClear benefitRecent studiesSignificant improvement